Concentrations of Tenofovir and Emtricitabine in Saliva: Implications for Preexposure Prophylaxis of Oral HIV Acquisition

Victoire de Lastours, Julien Fonsart, Ruxandra Burlacu, B. Gourmel, Jean‐Michel Molina

Antimicrobial Agents and Chemotherapy · 2011 · 25 citations · 17 references

DOIFull text

Open access

Concepts

Abstract

To prevent acquisition of HIV through oral sex, drugs used for preexposure prophylaxis (Prep) need to diffuse in saliva. We measured tenofovir (TFV) and emtricitabine (FTC) concentrations simultaneously in the plasma and saliva of 41 HIV-infected patients under stable antiretroviral treatment. Mean ratios of saliva/plasma concentration were 3% (±4%) and 86.9% (±124%) for TFV and FTC, respectively. Tenofovir disoproxil fumarate (TDF) should be used in combination with FTC to prevent oral acquisition of HIV.

References

17